Unknown PHASE4 INTERVENTIONAL NCT01157455

A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization (SEEDS)

Clinical Trial Program of a Medical Instrument Product

Sponsor: CCRF Consulting Co., Ltd.

Interventions Aspirin Clopidogrel Everolimus Drug Eluting Stent Heparin or Bivalirudin

Updated 6 times since 2017 Last updated: Jul 8, 2010 Started: May 31, 2010 Primary completion: Mar 31, 2012 Completion: Jun 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Coronary Artery Diseases, this trial is ongoing. The trial is conducted by CCRF Consulting Co., Ltd. and has accumulated 6 data snapshots since 2010. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE4

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CCRF Consulting Co., Ltd.

Data source: CCRF Consulting Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China